1887

Abstract

A high prevalence of the rtI187V polymerase substitution of hepatitis B virus (HBV) was detected in nucleoside/nucleotide-analogue-naive and -treated chronic hepatitis B (CHB) patients. We aimed at assessing the replicative capacity and susceptibility to lamivudine (LAM) and adefovir (ADV) of HBV harbouring rtI187V alone or in conjunction with LAM- or ADV-resistant mutations. The reverse transcriptase region of HBV isolates was directly sequenced from a cohort of 300 CHB patients from China. Replication-competent HBV constructs containing rtI187V and combined with LAM-resistant (rtM204I, rtL180M/rtM204V) mutations were generated, and compared with WT, LAM-resistant single (rtM204I) or double (rtL180M/rtM204V) and ADV-resistant (rtN236T) clones. In a Chinese cohort of 300 CHB patients, 8.7 % (26/300) showed substitution of rtI187 with V. Of note, the rtI187V prevalence in HBV genotype B was significantly higher than that in HBV genotype C (95.2 vs 4.8 %). phenotypic assays showed that the viruses bearing the rtI187V substitution had impaired replication efficacy when compared with the WT and the virus carrying rtI187V combined with LAM-resistant single or double mutations showed even more significantly impaired replicative capacities. Furthermore, rtI187V HBV remained susceptible towards treatment with LAM or ADV whereas the combination of the rtI187V substitution with LAM-resistant mutations rendered HBV resistant to LAM but still sensitive to ADV. Our study revealed that the rtI187V substitution in the HBV polymerase frequently occurred in CHB patients, particularly those with HBV genotype B. However, the emergence of the rtI187V substitution significantly impaired viral replication but without affecting drug sensitivity .

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.066886-0
2014-11-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/11/2523.html?itemId=/content/journal/jgv/10.1099/vir.0.066886-0&mimeType=html&fmt=ahah

References

  1. Amini-Bavil-Olyaee S., Herbers U., Sheldon J., Luedde T., Trautwein C., Tacke F.. ( 2009a;). The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. . Hepatology 49:, 1158–1165. [CrossRef][PubMed]
    [Google Scholar]
  2. Amini-Bavil-Olyaee S., Herbers U., Mohebbi S. R., Sabahi F., Zali M. R., Luedde T., Trautwein C., Tacke F.. ( 2009b;). Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. . J Hepatol 51:, 647–654. [CrossRef][PubMed]
    [Google Scholar]
  3. Bock C. T., Tillmann H. L., Torresi J., Klempnauer J., Locarnini S., Manns M. P., Trautwein C.. ( 2002;). Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. . Gastroenterology 122:, 264–273. [CrossRef][PubMed]
    [Google Scholar]
  4. Brunelle M. N., Jacquard A. C., Pichoud C., Durantel D., Carrouée-Durantel S., Villeneuve J. P., Trépo C., Zoulim F.. ( 2005;). Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. . Hepatology 41:, 1391–1398. [CrossRef][PubMed]
    [Google Scholar]
  5. Chae H. B., Hann H. W.. ( 2007;). Time for an active antiviral therapy for hepatitis B: an update on the management of hepatitis B virus infection. . Ther Clin Risk Manag 3:, 605–612.[PubMed]
    [Google Scholar]
  6. Doo E., Liang T. J.. ( 2001;). Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. . Gastroenterology 120:, 1000–1008. [CrossRef][PubMed]
    [Google Scholar]
  7. Fu L., Cheng Y. C.. ( 1998;). Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. . Biochem Pharmacol 55:, 1567–1572. [CrossRef][PubMed]
    [Google Scholar]
  8. Fu L., Cheng Y. C.. ( 2000;). Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. . Antimicrob Agents Chemother 44:, 3402–3407. [CrossRef][PubMed]
    [Google Scholar]
  9. Fu L., Wu X., Kong Y. Y., Wang Y.. ( 1996;). Regulation of hepatitis B virus gene expression by its two enhancers. . Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 28:, 590–599.[PubMed]
    [Google Scholar]
  10. Fung J., Lai C. L., Seto W. K., Yuen M. F.. ( 2011;). Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. . J Antimicrob Chemother 66:, 2715–2725. [CrossRef][PubMed]
    [Google Scholar]
  11. Krishnan P., Liou J. Y., Cheng Y. C.. ( 2002;). Phosphorylation of pyrimidine l-deoxynucleoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. . J Biol Chem 277:, 31593–31600. [CrossRef][PubMed]
    [Google Scholar]
  12. Lada O., Benhamou Y., Cahour A., Katlama C., Poynard T., Thibault V.. ( 2004;). In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. . Antivir Ther 9:, 353–363.[PubMed]
    [Google Scholar]
  13. Lam Y. F., Yuen M. F., Seto W. K., Lai C. L.. ( 2011;). Current antiviral therapy of chronic hepatitis B: efficacy and safety. . Curr Hepat Rep 10:, 235–243. [CrossRef][PubMed]
    [Google Scholar]
  14. Lim Y. S., Lee J. Y., Lee D., Shim J. H., Lee H. C., Lee Y. S., Suh D. J.. ( 2012;). Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. . Antimicrob Agents Chemother 56:, 2941–2947. [CrossRef][PubMed]
    [Google Scholar]
  15. Lu F. M., Zhuang H.. ( 2009;). Management of hepatitis B in China. . Chin Med J (Engl) 122:, 3–4.[PubMed]
    [Google Scholar]
  16. Malik A., Singhal D. K., Albanyan A., Husain S. A., Kar P.. ( 2012;). Hepatitis B virus gene mutations in liver diseases: a report from New Delhi. . PLoS ONE 7:, e39028. [CrossRef][PubMed]
    [Google Scholar]
  17. Melegari M., Scaglioni P. P., Wands J. R.. ( 1998;). Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. . Hepatology 27:, 628–633. [CrossRef][PubMed]
    [Google Scholar]
  18. Min A. D., Dienstag J. L.. ( 2007;). Oral antivirals for chronic hepatitis B. . Clin Liver Dis 11:, 851–868, ix. [CrossRef][PubMed]
    [Google Scholar]
  19. Papatheodoridis G. V., Manolakopoulos S., Archimandritis A. J.. ( 2008;). Current treatment indications and strategies in chronic hepatitis B virus infection. . World J Gastroenterol 14:, 6902–6910. [CrossRef][PubMed]
    [Google Scholar]
  20. Suk F. M., Lin M. H., Newman M., Pan S., Chen S. H., Liu J. D., Shih C.. ( 2002;). Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (I97L) in human hepatitis B virus. . J Virol 76:, 12069–12077. [CrossRef][PubMed]
    [Google Scholar]
  21. Tacke F., Manns M. P., Trautwein C.. ( 2004a;). Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance–implications for novel antiviral strategies. . Curr Med Chem 11:, 2667–2677. [CrossRef][PubMed]
    [Google Scholar]
  22. Tacke F., Gehrke C., Luedde T., Heim A., Manns M. P., Trautwein C.. ( 2004b;). Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. . J Virol 78:, 8524–8535. [CrossRef][PubMed]
    [Google Scholar]
  23. Tillmann H. L.. ( 2007;). Antiviral therapy and resistance with hepatitis B virus infection. . World J Gastroenterol 13:, 125–140. [CrossRef][PubMed]
    [Google Scholar]
  24. Warner N., Locarnini S., Kuiper M., Bartholomeusz A., Ayres A., Yuen L., Shaw T.. ( 2007;). The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. . Antimicrob Agents Chemother 51:, 2285–2292. [CrossRef][PubMed]
    [Google Scholar]
  25. Yeh C. T., Chen T., Hsu C. W., Chen Y. C., Lai M. W., Liang K. H., Chen T. C.. ( 2011;). Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. . BMC Cancer 11:, 398. [CrossRef][PubMed]
    [Google Scholar]
  26. Yim H. J., Hussain M., Liu Y., Wong S. N., Fung S. K., Lok A. S.. ( 2006;). Evolution of multi-drug resistant hepatitis B virus during sequential therapy. . Hepatology 44:, 703–712. [CrossRef][PubMed]
    [Google Scholar]
  27. Zhang A. M., Wang H. F., Wang H. B., Su H. B., Xin S. J., Hu J. H., You S. L.. ( 2011;). [Distribution and clinical significance of HBV genotypes in patients with HBV infection in 30 regions of China]. . Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 25:, 126–128.[PubMed]
    [Google Scholar]
  28. Zheng J., Zeng Z., Zhang D., Yu Y., Wang F., Pan C. Q.. ( 2012;). Prevalence and significance of hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. . Liver Int 32:, 1535–1542. [CrossRef][PubMed]
    [Google Scholar]
  29. Zhong Y., Lv J., Li J., Xing X., Zhu H., Su H., Chen L., Zhou X.. ( 2012;). Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B. . Antiviral Res 93:, 185–190. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.066886-0
Loading
/content/journal/jgv/10.1099/vir.0.066886-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error